Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia.

Muller AE, Punt N, Mouton JW.

Antimicrob Agents Chemother. 2014 May;58(5):2512-9. doi: 10.1128/AAC.02611-13. Epub 2014 Feb 10.

2.

Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia.

Muller AE, Punt N, Mouton JW.

J Antimicrob Chemother. 2013 Apr;68(4):900-6. doi: 10.1093/jac/dks468. Epub 2012 Nov 28.

3.

Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia.

MacVane SH, Kuti JL, Nicolau DP.

Antimicrob Agents Chemother. 2014;58(3):1359-64. doi: 10.1128/AAC.01463-13. Epub 2013 Dec 16.

4.

A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.

Awad SS, Rodriguez AH, Chuang YC, Marjanek Z, Pareigis AJ, Reis G, Scheeren TW, Sánchez AS, Zhou X, Saulay M, Engelhardt M.

Clin Infect Dis. 2014 Jul 1;59(1):51-61. doi: 10.1093/cid/ciu219. Epub 2014 Apr 9.

5.

Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections.

Kimko H, Xu X, Nandy P, Samtani MN, Strauss RS, Bagchi P, Noel GJ.

Antimicrob Agents Chemother. 2009 Aug;53(8):3371-4. doi: 10.1128/AAC.01653-08. Epub 2009 Jun 15.

6.

Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.

Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Noreddin AM, Karlowsky JA.

Am J Clin Dermatol. 2008;9(4):245-54. Review.

PMID:
18572975
7.

Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.

Crandon JL, Bulik CC, Kuti JL, Nicolau DP.

Antimicrob Agents Chemother. 2010 Mar;54(3):1111-6. doi: 10.1128/AAC.01183-09. Epub 2009 Dec 28.

9.

Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia.

Aitken SL, Altshuler J, Guervil DJ, Hirsch EB, Ostrosky-Zeichner LL, Ericsson CD, Tam VH.

Int J Antimicrob Agents. 2015 May;45(5):541-4. doi: 10.1016/j.ijantimicag.2014.12.018. Epub 2015 Jan 19.

PMID:
25665726
10.

Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study.

Muller AE, Schmitt-Hoffmann AH, Punt N, Mouton JW.

Antimicrob Agents Chemother. 2013 May;57(5):2047-53. doi: 10.1128/AAC.02292-12. Epub 2013 Feb 12.

11.

Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.

McKinnon PS, Paladino JA, Schentag JJ.

Int J Antimicrob Agents. 2008 Apr;31(4):345-51. doi: 10.1016/j.ijantimicag.2007.12.009. Epub 2008 Mar 4.

PMID:
18313273
12.

Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.

Lodise TP Jr, Pypstra R, Kahn JB, Murthy BP, Kimko HC, Bush K, Noel GJ, Drusano GL.

Antimicrob Agents Chemother. 2007 Jul;51(7):2378-87. Epub 2007 Mar 26.

13.

Pharmacodynamic analysis of the microbiological efficacy of telithromycin in patients with community-acquired pneumonia.

Shi J, Pfister M, Jenkins SG, Chapel S, Barrett JS, Port RE, Howard D.

Clin Pharmacokinet. 2005;44(3):317-29.

PMID:
15762772
14.

Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

Rodvold KA, Nicolau DP, Lodise TP, Khashab M, Noel GJ, Kahn JB, Gotfried M, Murray SA, Nicholson S, Laohavaleeson S, Tessier PR, Drusano GL.

Antimicrob Agents Chemother. 2009 Aug;53(8):3294-301. doi: 10.1128/AAC.00144-09. Epub 2009 May 18.

15.

Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.

Lagacé-Wiens PR, Rubinstein E.

Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):789-99. doi: 10.1517/17425255.2013.788150. Epub 2013 Apr 17. Review.

PMID:
23590397
16.
17.

Modeling the response of pneumonia to antimicrobial therapy.

Hyatt JM, Luzier AB, Forrest A, Ballow CH, Schentag JJ.

Antimicrob Agents Chemother. 1997 Jun;41(6):1269-74.

18.

Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline.

Bhavnani SM, Rubino CM, Hammel JP, Forrest A, Dartois N, Cooper CA, Korth-Bradley J, Ambrose PG.

Antimicrob Agents Chemother. 2012 Feb;56(2):1065-72. doi: 10.1128/AAC.01615-10. Epub 2011 Dec 5.

19.

Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.

Syed YY.

Drugs. 2014 Sep;74(13):1523-42. doi: 10.1007/s40265-014-0273-x. Review.

PMID:
25117196
20.

In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.

Craig WA, Andes DR.

Antimicrob Agents Chemother. 2008 Oct;52(10):3492-6. doi: 10.1128/AAC.01273-07. Epub 2008 Aug 1.

Items per page

Supplemental Content

Write to the Help Desk